Compare Microchip Technology Inc. (MCHP) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs BIO-TECHNE Corp — how do they compare? Microchip Technology Inc. trades at $76.45 (market cap $42.37B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Microchip Technology Inc. is far larger — about 3.7× BIO-TECHNE Corp's market cap, and Microchip Technology Inc. pays the higher dividend (2.33%). Which is the better fit depends on your goals — on Pluang, investors hold Microchip Technology Inc. for 62 Days and BIO-TECHNE Corp for 63 Days on average.
| MCHP | TECH | |
|---|---|---|
Market Cap | $42.37B | $11.37B |
Volume | 8,887,625 | 3,153,511 |
Sector | Technology | Health |
52-Week High | $102.97 | $72.61 |
52-Week Low | $49.02 | $43.31 |
Typical Hold Time | 62 Days | 63 Days |
Enterprise Value | $47.49B | $11.40B |
Dividend Yield | 2.33% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHP trades at $75.52, down 7.06% over 24 hours amid a bearish technical signal. The company reported a net loss of -$500K for 2025, though it has beaten EPS estimates for the last three quarters. Analyst consensus is strongly bullish with a $110.50 price target, and recent news highlights expansion in Ethernet and 48V power portfolios, plus the completed acquisition of Hailo to bolster edge AI capabilities.
The outlook is mixed: strong analyst support and strategic acquisitions in growth areas like AI and data centers present upside, but high valuation ratios, significant debt, and recent profitability challenges pose risks. The stock's near-term performance will hinge on Q3 2026 earnings and execution in high-demand semiconductor segments.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
